Hyaluronic acid-artesunate-polyarginine nanoparticles, preparation method and application

By covalently coupling artesunate with hyaluronic acid and polyarginine, hyaluronic acid-artesunate-polyarginine nanoparticles were prepared, and the tissue phase of artesunate in eye medicine was solved. The problems of poor volume and poor efficacy have achieved significant inhibition of neovascularization in the eye and improvement of drug penetration.

CN118146569BActive Publication Date: 2024-11-22OCEAN UNIV OF CHINA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410100369.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-24
Publication Date
2024-11-22
Estimated Expiration
2044-01-24

AI Technical Summary

Technical Problem

The existing artesunate has poor histocompatibility and strong irritation in antimalarial and other fields, making it difficult to effectively exert its therapeutic activity, especially when taking medication in the eyes, which makes it difficult to penetrate the tissue barrier, resulting in poor efficacy. good.

Method used

By covalently coupling artesunate with hyaluronic acid and polyarginine, using adipic acid dihydrazide as the connecting arm, NCA ring-opening polymerization was performed, and hyaluronic acid-artesunate was prepared by combining ultrasound method. Polyarginine nanoparticles enhance their biocompatibility and tissue penetration.

Benefits of technology

The biocompatibility and sustained release effect of artesunate was achieved, which significantly inhibited neovascularization in the eye, improved the tissue penetration and efficacy of the drug, extended the drug action time, and reduced the number of medications and irritation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118146569B_ABST
    Figure CN118146569B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of compound synthesis, and discloses hyaluronic acid-artesunate-polyarginine nanoparticles, preparation methods and applications. The method uses adipic acid dihydrazide as a connecting arm, and the amino groups at both ends of adipic acid dihydrazide are respectively connected to the carboxyl group of hyaluronic acid and the carboxyl end of artesunate to prepare a hyaluronic acid-artesunate polymer; by ring-opening polymerization of NCA, polyornithine is grafted at the carboxyl end of hyaluronic acid, and a polymer of hyaluronic acid and polyarginine is prepared by guanidating the amino end of ornithine; by mixing the above-prepared hyaluronic acid-artesunate and hyaluronic acid-polyarginine compounds, an ultrasonic method is used to prepare hyaluronic acid-artesunate-polyarginine nanoparticles. The present invention has a new application site, increases the scope of drug adaptation, and is suitable for the synthesis of covalent polymers of hyaluronic acid and artesunate of different molecular weights. It can be used to prepare ocular anti-neovascular drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of compound synthesis, and in particular relates to hyaluronic acid-artesunate-polyarginine nanoparticles, a preparation method and application thereof. Background Art

[0002] Hyaluronic acid (HA) is a long straight-chain, non-sulfated macromolecular anionic polysaccharide, also known as hyaluronic acid and hyaluronic acid. It is composed of disaccharide units composed of β-1,3-glycosidic bonds of D-glucuronic acid and DN-acetamido glucose connected alternately. The molar molecular weight of HA ranges from hundreds to hundreds of thousands. Its physical and chemical properties are excellent. Its structural advantages give it excellent cell compatibility, physiological degradability and high affinity with water. Hyaluronic acid has good tissue compatibility, safety, targeting, biodegradability and high drug loading. It can be used as a viscoelastic agent in various ophthalmic surgeries, as a carrier for a variety of drugs such as polypeptide protein drugs and gene drugs, and because of its unique physical and chemical properties, it is often used as a component of eye drops. It plays an irreplaceable and important role in the medical field.

[0003] Artesunate is derived from the leaves of Artemisia annua, a plant of the Asteraceae family. It can kill the asexual forms of Plasmodium and has a certain control effect on the occurrence of malaria. It is mainly used as an antimalarial drug and has shown excellent characteristics of low toxicity and small side effects in the long-term treatment of malaria. More and more studies have shown that in addition to its antimalarial effect, artesunate also has a therapeutic effect on asthma, colitis, and cervical cancer, esophageal cancer, liver cancer and other cancers.

[0004] Studies have found that artesunate can significantly downregulate the expression of VEGF2 and its related mRNA and protein in liver cancer cells compared with the control group, and can inhibit the formation of tumor blood vessels. Studies have shown that artesunate can also reduce the expression of VEGF receptors Flt-1 and KDR / flk-1, thereby resisting angiogenesis. Artesunate has a definite anti-angiogenic effect. The application of artesunate is limited by some of its own shortcomings, but its active advantages in the antimalarial field and other fields that are being discovered have led to a gradual deepening of its research and development. Summary of the invention

[0005] In order to overcome the problems existing in the related art, the embodiments disclosed in the present invention provide hyaluronic acid-artesunate-polyarginine nanoparticles, preparation methods and applications thereof, and specifically relate to the preparation methods of hyaluronic acid-artesunate-polyarginine nanoparticles and applications thereof in the preparation of ocular anti-angiogenic drugs and health products.

[0006] The technical scheme is as follows: A method for preparing hyaluronic acid-artesunate-polyarginine nanoparticles, comprising:

[0007] S1, using adipic acid dihydrazide as a connecting arm, the amino groups at both ends of adipic acid dihydrazide are connected to the carboxyl group of hyaluronic acid and the carboxyl end of artesunate, respectively, to prepare a hyaluronic acid-artesunate polymer;

[0008] S2, by ring-opening polymerization of NCA, polyornithine was grafted onto the carboxyl end of hyaluronic acid, and the amino end of ornithine was guanidated to prepare a polymer of hyaluronic acid and polyarginine;

[0009] S3, preparing hyaluronic acid-artesunate-polyarginine nanoparticles by mixing hyaluronic acid-artesunate and hyaluronic acid-polyarginine compounds using an ultrasonic method.

[0010] In step S1, the general structural formula of the hyaluronic acid-artesunate polymer is as follows:

[0011]

[0012] Among them, n=1-2500.

[0013] Furthermore, the molecular weight of the hyaluronic acid is 0.38-100 kDa, and it is used to prepare artesunate derivatives of different molecular weights and different physical and chemical properties. The disaccharide units of the artesunate derivatives are composed of D-glucuronic acid and N-acetylglucosamine connected by β-1,4 glycosidic bonds, and the disaccharide units are connected by β-1,4 glycosidic bonds;

[0014] The connecting chain between hyaluronic acid and artesunate derivatives is characterized by amino groups and hydrazide groups at both ends of the chain, and a length of 2-12 carbons in the middle, including dihydrazide and diamine compounds, which are used to prepare hyaluronic acid and artesunate covalent conjugates with different bridging arms.

[0015] In step S1, the preparation of hyaluronic acid-artesunate polymer comprises:

[0016] (1) Dissolve hyaluronic acid HA in deionized water, stir at 25°C until the hyaluronic acid is completely dissolved, add the linker adipic acid dihydrazide ADH after the hyaluronic acid is completely dissolved, adjust the pH value of the reaction liquid to 4-5 with 0.1mM hydrochloric acid, add an equal amount of ethanol to the reaction liquid, mix well, add 1-ethyl-(3-dimethylaminopropyl) carbodiimide EDC and N-hydroxysuccinimide NHS in turn, and react at room temperature for 8 hours; after the reaction is completed, add sodium chloride salt solution, mix well, add anhydrous ethanol to precipitate, centrifuge for 10 minutes, and precipitate; add sodium chloride solution to dissolve again, continue to precipitate, repeat 3 times, collect the precipitate, dialyze for 48 hours, concentrate under reduced pressure, and freeze-dry to obtain hyaluronic acid derivative HA-ADH with amino group in hyaluronic acid carboxyl group;

[0017] (2) Artesunate was dissolved in formamide, and 1-ethyl-(3-dimethylaminopropyl) carbodiimide EDC and N-hydroxysuccinimide NHS were added in sequence. The mixture was reacted at 4°C in the dark for 30 minutes. The obtained hyaluronic acid derivative HA-ADH was dissolved in dimethylformamide with an equal volume to formamide. The activated artesunate solution was added to the hyaluronic acid solution under ice bath. The mixture was reacted at 10°C in the dark for 12 hours. After the reaction, the mixture was dialyzed in a solution of ethanol: water = 1:1 using a dialysis bag with a molecular weight cutoff of 3500Da. The solution was changed every 8 hours. After one day of dialysis, the mixture was dialyzed with deionized water for one day. The water was changed every 8 hours. After dialysis, the mixture was concentrated and freeze-dried to obtain the hyaluronic acid-artesunate polymer HA-ART.

[0018] In step S2, the general structural formula of the polymer of hyaluronic acid and polyarginine is:

[0019]

[0020] Wherein, n=1-2500, m=1-30.

[0021] Furthermore, the preparation method of the polymer of hyaluronic acid and polyarginine comprises:

[0022] (i) dissolving N'-tert-butyloxycarbonyl-L-ornithine Boc-Orn in anhydrous tetrahydrofuran, stirring at 25° C., adding epichlorohydrin, adding triphosgene, stirring and mixing, and reacting at room temperature for 3 hours; after the reaction, adding cold deionized water to quench the triphosgene, extracting with ethyl acetate, collecting the organic phase and drying it by rotary evaporation, dissolving it in anhydrous tetrahydrofuran, adding anhydrous n-hexane to precipitate, collecting the precipitate and drying it by rotary evaporation, repeating this process for 3 times, collecting the precipitate, and drying it by rotary evaporation to obtain N'-tert-butyloxycarbonyl-L-ornithine-N-carboxyl cyclic anhydride (Boc-Orn-NCA);

[0023] (ii) dissolving the hyaluronic acid derivative HA-ADH prepared from the hyaluronic acid-artesunate polymer in deionized water, adding NaCO3, and stirring at 25°C until completely dissolved; dissolving Boc-Orn-NCA in a dimethylformamide / chloroform mixed solution; mixing the above two solutions, stirring at room temperature for 12 hours, adding cold water to precipitate after the reaction, collecting the precipitate by centrifugation and drying, and obtaining a hyaluronic acid-grafted polyornithine compound HA-p-Boc-Orn with terminal Boc protection;

[0024] (iii) dissolving the prepared HA-p-Boc-Orn in trifluoroacetic acid, stirring at room temperature for 3 hours, adding ether to precipitate after the reaction, dissolving with deionized water and dialyzing, concentrating and freeze-drying after dialysis to obtain a hyaluronic acid-grafted polyornithine compound HA-p-Orn;

[0025] (iv) The prepared HA-p-Orn was dissolved in deionized water, NaOH was added, and the mixture was stirred at room temperature for 3 hours. Methoxyisourea sulfate was added, and the mixture was reacted in an oil bath at 65°C for 30 minutes. After the reaction, the mixture was purified using a gel chromatography column, and the sample solution was freeze-dried to obtain the hyaluronic acid-grafted polyarginine compound HA-p-Arg.

[0026] In step S3, the mixing of hyaluronic acid-artesunate and hyaluronic acid-polyarginine compounds includes: dissolving the hyaluronic acid-artesunate polymer HA-ART and the hyaluronic acid-polyarginine HA-p-Arg compound in deionized water, swelling at 4°C for 12 hours, sonicating on ice, dissolving the freeze-dried powder in deionized water after freeze-drying, and self-packing at 4°C to obtain a hyaluronic acid-artesunate-polyarginine nanoparticle solution @HA-ART-p-Arg.

[0027] Another object of the present invention is to provide a hyaluronic acid-artesunate-polyarginine nanoparticle, which is prepared by the preparation method of hyaluronic acid-artesunate-polyarginine nanoparticles, wherein artesunate / polyarginine=0.01-10; and the hyaluronic acid-artesunate polymer and the hyaluronic acid-polyarginine compound are ultrasonically treated to obtain the hyaluronic acid-artesunate polymer and the hyaluronic acid-polyarginine nanoparticle through self-assembly.

[0028] Another object of the present invention is to provide a use of a hyaluronic acid-artesunate polymer HA-ART prepared from hyaluronic acid-artesunate-polyarginine nanoparticles in the preparation of a drug for treating and / or preventing ocular neovascular diseases.

[0029] Furthermore, the drug for treating and / or preventing ocular neovascular diseases includes drugs for treating and / or preventing corneal neovascular diseases, iris neovascular diseases, retinal neovascular diseases, choroidal neovascular diseases, and neovascular glaucoma diseases.

[0030] In combination with all the above technical solutions, the beneficial effects possessed by the present invention are as follows: the preparation method and application of hyaluronic acid-artesunate-polyarginine nanoparticles provided by the present invention include: hyaluronic acid, artesunate, preparing hyaluronic acid-artesunate polymer by chemical synthesis reaction, using adipic acid dihydrazide as a connecting arm, and connecting the carboxyl group of hyaluronic acid and the carboxyl end of artesunate to prepare hyaluronic acid-artesunate polymer by amino groups at both ends of adipic acid dihydrazide; by ring-opening polymerization of NCA, grafting polyornithine at the carboxyl end of hyaluronic acid, and preparing hyaluronic acid and polyarginine polymer by guanidating the amino end of ornithine; by mixing the above-prepared hyaluronic acid-artesunate and hyaluronic acid-polyarginine compounds, using ultrasonic method, preparing hyaluronic acid-artesunate-polyarginine nanoparticles. The present invention realizes the efficient synthesis of hyaluronic acid-artesunate polymer, hyaluronic acid-polyarginine compound and hyaluronic acid-artesunate-polyarginine nanoparticles.

[0031] The present invention first connects artesunate with adipic acid dihydrazide (ADH), and then connects it with the natural polymer material hyaluronic acid (HA) to obtain a hyaluronic acid-artesunate polymer. The hyaluronic acid-artesunate polymer improves the defects of the single material itself, and obtains a polymer HA-ART that has both the biocompatibility and biodegradability of natural polymers and good biological activity. The polymer has a significant inhibitory effect on HUVEC cells. The polymer can be used to prepare anti-tumor drugs and anti-ocular neovascularization drugs, and has great development potential.

[0032] The polymer obtained by the present invention can not only exert the activity of artesunate, but also exert the good tissue compatibility, drug loading and sustained release effect of hyaluronic acid, which can reduce the stimulation of eye medication, and can prolong the action time of the drug in the eye, reduce the number of eye medications, and increase the convenience and compliance of patients' medication. In addition, polyarginine has tissue permeability, which can guide nanoparticles to better penetrate tissue barriers to reach the site of action and better exert the drug effect. Compared with the use of artesunate alone, the polymer of the present invention can better exert the activity of artesunate, achieving the effect of "1+1>2".

[0033] The method of the invention has a new application part and increases the scope of drug application. The invention is suitable for the synthesis of covalent polymers of hyaluronic acid and artesunate with different molecular weights. The polymer can be used to prepare ocular anti-angiogenic drugs, health products and other sanitary products. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The accompanying drawings herein are incorporated in and constitute a part of the specification, illustrate embodiments consistent with the present disclosure, and together with the description, serve to explain the principles of the present disclosure;

[0035] Figure 1 It is a flow chart of the preparation method of hyaluronic acid-artesunate-polyarginine nanoparticles provided in an embodiment of the present invention;

[0036] Figure 2 It is a synthetic route map of hyaluronic acid-artesunate polymer (HA-ART) provided in an embodiment of the present invention;

[0037] Figure 3 This is a hydrogen nuclear magnetic spectrum of hyaluronic acid-artesunate polymer (HA-ART) provided in an embodiment of the present invention;

[0038] Figure 4 This is the infrared spectrum of hyaluronic acid-artesunate polymer (HA-ART) provided in the embodiment of the present invention

[0039] Figure 5 It is a synthetic route of a hyaluronic acid-polyarginine compound (HA-p-Arg) provided in an embodiment of the present invention;

[0040] Figure 6 This is a hydrogen nuclear magnetic spectrum of a hyaluronic acid-polyarginine compound (HA-p-Arg) provided in an embodiment of the present invention;

[0041] Figure 7 This is an infrared spectrum of a hyaluronic acid-polyarginine compound (HA-p-Arg) provided in an embodiment of the present invention;

[0042] Figure 8 It is a transmission electron micrograph of hyaluronic acid-artesunate-polyarginine nanoparticles (@HA-ART-p-Arg) provided in an embodiment of the present invention.

[0043] Fig. 9 This is a diagram showing the effect of hyaluronic acid-artesunate polymer (HA-ART) on cell proliferation provided by an embodiment of the present invention;

[0044] Fig.10 This is a diagram showing the effect of hyaluronic acid-artesunate polymer (HA-ART) on cell apoptosis provided by an embodiment of the present invention;

[0045] Fig.11 This is a graph showing the effect of hyaluronic acid-artesunate polymer (HA-ART) on cytokine VEGFR2 provided by an embodiment of the present invention;

[0046] Fig.12 This is a graph showing the effect of hyaluronic acid-artesunate polymer (HA-ART) on cytokine PKCα provided by an embodiment of the present invention;

[0047] Fig.13 This is a graph showing the effect of hyaluronic acid-artesunate polymer (HA-ART) on cytokine HIFα provided by an embodiment of the present invention;

[0048] Fig.14 This is a graph showing the effect of hyaluronic acid-artesunate polymer (HA-ART) on cytokine bFGF provided by an embodiment of the present invention;

[0049] Fig.15 This is a graph showing the effect of hyaluronic acid-artesunate polymer (HA-ART) on cytokine PDGFR provided by an embodiment of the present invention;

[0050] Fig.16 This is a graph showing the effect of a 500 μg group (7 days) of hyaluronic acid-artesunate polymer (HA-ART) provided in an embodiment of the present invention on corneal neovascularization in mice;

[0051] Fig.17 This is a graph showing the effect of the 750 μg group (7 days) of hyaluronic acid-artesunate polymer (HA-ART) provided in an embodiment of the present invention on corneal neovascularization in mice;

[0052] Fig.18 This is a graph showing the effect of the 1000 μg group (7 days) of hyaluronic acid-artesunate polymer (HA-ART) provided in an embodiment of the present invention on corneal neovascularization in mice. DETAILED DESCRIPTION

[0053] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below in conjunction with the accompanying drawings. In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present invention, so the present invention is not limited by the specific implementation disclosed below.

[0054] The hyaluronic acid-artesunate-polyarginine nanoparticles, preparation methods and applications provided by the embodiments of the present invention are innovative in that: the present invention prepares hyaluronic acid-polyarginine compounds based on the ring-opening polymerization of NCA for the first time, and prepares hyaluronic acid-artesunate-polyarginine nanoparticles by ultrasonic self-assembly. The nanoparticles have the therapeutic activity of artesunate, the biocompatibility of hyaluronic acid and the membrane-penetrating effect of polyarginine, have sustained-release and synergistic effects, and play an important role in developing new applications and new dosage forms of artesunate drugs.

[0055] In the present invention, the good biocompatibility of hyaluronic acid is used as an excellent drug carrier with good tissue compatibility, safety and high drug loading capacity, and also has the function of sustained release of drugs, which makes hyaluronic acid have great advantages in ophthalmic medication. The present invention designs and prepares a copolymer of hyaluronic acid loaded with artesunate to improve the tissue compatibility of artesunate and prolong the action time of artesunate in the eye. The polymer can be used to prepare ocular anti-angiogenic drugs, health products and other sanitary products.

[0056] Example 1: The preparation method of hyaluronic acid-artesunate-polyarginine nanoparticles provided in the embodiment of the present invention comprises:

[0057] S1, using adipic acid dihydrazide as a connecting arm, the amino groups at both ends of adipic acid dihydrazide are connected to the carboxyl group of hyaluronic acid and the carboxyl end of artesunate, respectively, to prepare a hyaluronic acid-artesunate polymer;

[0058] S2, by ring-opening polymerization of NCA, polyornithine was grafted onto the carboxyl end of hyaluronic acid, and the amino end of ornithine was guanidated to prepare a polymer of hyaluronic acid and polyarginine;

[0059] S3, preparing hyaluronic acid-artesunate-polyarginine nanoparticles by mixing hyaluronic acid-artesunate and hyaluronic acid-polyarginine compounds using an ultrasonic method.

[0060] In step S1 of the embodiment of the present invention, the hyaluronic acid-artesunate polymer has a general structural formula as shown below:

[0061]

[0062] In the structural formula of the hyaluronic acid-artesunate polymer, n=1 to 2500. The hyaluronic acid-artesunate polymer is obtained by firstly modifying the carboxyl group of hyaluronic acid with amino groups, and then reacting the amino groups with the carboxyl groups at the end of artesunate to form an amide bond.

[0063] That is, the hyaluronic acid-artesunate is obtained by first reacting the carboxyl group of hyaluronic acid with a connecting wall having amino groups and hydrazide groups at both ends to form an amide bond, introducing amino groups and hydrazide groups, and then newly introducing amino groups and hydrazide groups to form an amide bond with the carboxyl group of artesunate.

[0064] The specific reaction steps are as follows:

[0065] (1) Dissolve hyaluronic acid (HA) in deionized water and stir at 25°C until the hyaluronic acid is completely dissolved. After the hyaluronic acid is completely dissolved, add the linker adipic acid dihydrazide (ADH), adjust the pH value of the reaction liquid to 4-5 with 0.1mM hydrochloric acid, then add an equal amount of ethanol to the reaction liquid, mix well, add 1-ethyl-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) in sequence, and react at room temperature for 8 hours. After the reaction is completed, add an appropriate volume of sodium chloride solution, mix well, add anhydrous ethanol to precipitate, centrifuge for 10 minutes, add an appropriate amount of sodium chloride solution to dissolve the precipitate again, continue to precipitate, repeat 3 times, collect the precipitate, dialyze for 48 hours, concentrate under reduced pressure, and freeze-dry to obtain a hyaluronic acid derivative with an amino group on the hyaluronic acid carboxyl group (HA-ADH).

[0066] Among them, the invention innovatively adds an equal volume of ethanol to the reaction solution, which greatly increases the modification degree of ADH, and the modification degree can reach up to 50%;

[0067] (2) Artesunate was dissolved in formamide, and 1-ethyl-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) were added in sequence. The mixture was reacted at 4°C in the dark for 30 minutes. The hyaluronic acid derivative (HA-ADH) obtained above was dissolved in dimethylformamide with an equal volume to formamide. The activated artesunate solution was added to the hyaluronic acid solution under ice bath. The mixture was reacted at 10°C in the dark for 12 hours. After the reaction, the mixture was dialyzed in a solution of ethanol: water = 1:1 using a dialysis bag with a molecular weight cutoff of 3500 Da. The solution was changed every 8 hours. After one day of dialysis, the mixture was dialyzed with deionized water for another day. The water was changed every 8 hours. After dialysis, the hyaluronic acid-artesunate polymer (HA-ART) was obtained by concentration and freeze-drying.

[0068] In step S2 of the embodiment of the present invention, the present invention innovatively proposes a hyaluronic acid-polyarginine compound, the general structural formula of which is as follows:

[0069]

[0070] In the prior art, hyaluronic acid and polyarginine are used in combination for sterilization, delivery and preparation of hydrogels, but most of them are prepared by utilizing the electrostatic interaction between the anions carried by hyaluronic acid and the cations of polyarginine, and a few are connected by covalent bonds. Moreover, the connecting arms and connecting sites of the prior art are different from those of the present invention.

[0071] In the present invention, in the structural formula of the hyaluronic acid-polyarginine compound, n=1-2500, m=1-30. The hyaluronic acid-polyarginine compound is prepared by firstly modifying the carboxyl group of hyaluronic acid with amino groups, and then initiating the ring-opening polymerization of N'-tert-butyloxycarbonyl-L-ornithine-N-carboxyl cyclic anhydride (Boc-Orn-NCA) with the amino group, and then removing the Boc group and then guanidating the terminal amino group of ornithine. The specific reaction steps are as follows:

[0072] (i) N'-tert-butyloxycarbonyl-L-ornithine (Boc-Orn) is dissolved in anhydrous tetrahydrofuran, stirred at 25°C, epichlorohydrin is added, and then triphosgene is slowly added, stirred and mixed, and reacted at room temperature for 3 hours. After the reaction is completed, an appropriate amount of cold deionized water is added to quench the triphosgene, and then extracted with ethyl acetate, the organic phase is collected and dried by rotary evaporation, dissolved in anhydrous tetrahydrofuran, anhydrous n-hexane is added to precipitate, the precipitate is collected and dried by rotary evaporation, and the precipitate is collected and dried by rotary evaporation. After repeating the process for 3 times, the precipitate is collected and dried by rotary evaporation to obtain N'-tert-butyloxycarbonyl-L-ornithine-N-carboxyl cyclic anhydride (Boc-Orn-NCA).

[0073] (ii) dissolving the HA-ADH prepared in step (1) of the preparation of the hyaluronic acid-artesunate polymer in deionized water, adding NaCO3, and stirring at 25°C until completely dissolved; dissolving the Boc-Orn-NCA prepared in step (i) in a dimethylformamide / chloroform mixed solution; mixing the above two solutions, stirring vigorously at room temperature for 12 hours, adding cold water to precipitate after the reaction, collecting the precipitate by centrifugation, and drying to obtain a hyaluronic acid-grafted poly-ornithine compound with terminal Boc protection (HA-p-Boc-Orn).

[0074] The present invention innovatively proposes: utilizing the hydrazide group introduced on HA to initiate the ring-opening polymerization of Boc-Orn-NCA, thereby coupling polyarginine on hyaluronic acid. This method is highly flexible and can control the degree of polymerization of polyarginine by controlling the reaction equivalent. The bridging arm between hyaluronic acid and polyarginine can be replaced by other bridging arms with amino groups or hydrazide.

[0075] (iii) The HA-p-Boc-Orn prepared in step (ii) is dissolved in trifluoroacetic acid, stirred at room temperature for 3 hours, and after the reaction is completed, ether is added for precipitation, and the mixture is dissolved in deionized water and dialyzed. After the dialyzation, the mixture is concentrated and freeze-dried to obtain a hyaluronic acid-grafted polyornithine compound (HA-p-Orn).

[0076] (iv) The HA-p-Orn prepared in step (iii) was dissolved in deionized water, an appropriate amount of NaOH was added, and the mixture was stirred at room temperature for 3 hours. Methoxyisourea sulfate was added, and the mixture was reacted in an oil bath at 65°C for 30 minutes. After the reaction, the mixture was purified using a gel chromatography column. The sample solution was freeze-dried to obtain a hyaluronic acid-grafted polyarginine compound (HA-p-Arg).

[0077] It can be understood that the prior art purification process after guanidation requires dialysis purification, while the present invention uses gel purification.

[0078] In step S3 of the embodiment of the present invention, the ratio of artesunate to polyarginine in the hyaluronic acid-artesunate-polyarginine nanoparticles is 0.01 to 10. The hyaluronic acid-artesunate-polyarginine nanoparticles are firstly prepared by ultrasonically treating a mixture of a hyaluronic acid-artesunate polymer and a hyaluronic acid-polyarginine compound, and then self-assembling the mixture. The specific reaction steps are as follows:

[0079] The hyaluronic acid-artesunate polymer (HA-ART) and the hyaluronic acid-polyarginine (HA-p-Arg) compound were dissolved in deionized water in a certain proportion, swelled at 4°C for 12 hours, sonicated on ice, freeze-dried and then the lyophilized powder was dissolved in deionized water, and self-packed at 4°C to obtain the hyaluronic acid-artesunate-polyarginine nanoparticle solution (@HA-ART-p-Arg).

[0080] In the embodiment of the present invention, the molecular weight of hyaluronic acid is 0.38-100kDa, and it can be used to prepare hyaluronic acid derivatives and artesunate derivatives with different molecular weights and different physical and chemical properties. Its disaccharide unit is composed of D-glucuronic acid and N-acetylglucosamine connected by β-1,4 glycosidic bonds, and the disaccharide units are connected by β-1,4 glycosidic bonds.

[0081] In an embodiment of the present invention, the connecting chain between the hyaluronic acid and artesunate is characterized by having amino groups and hydrazide groups at both ends of the chain, a length of 2 to 12 carbons in the middle, including dihydrazide and diamine compounds, which can be used to prepare hyaluronic acid and artesunate covalent conjugates with different bridging arms.

[0082] In the embodiments of the present invention, hyaluronic acid-artesunate polymer (HA-ART) has the effect of inhibiting angiogenesis, showing an inhibitory effect on the proliferation of human umbilical vein endothelial cells (HUVEC), and the inhibitory effect on cell proliferation is positively correlated with concentration and time.

[0083] Specifically, HUVEC cells in the logarithmic growth phase and in good growth condition were taken and cultured at 5×10 3Cells were inoculated into 96-well cell culture plates and cultured overnight in a 37°C, 5% CO2 incubator. Different concentrations of hyaluronic acid-artesunate polymers were added for stimulation for 72 hours. Cell proliferation activity was detected by CCK8 method.

[0084] HUVEC cells in the logarithmic growth phase and in good growth condition were taken and cultured at 5×10 5 Cells were inoculated into 6-well cell culture plates and cultured overnight in a 37°C, 5% CO2 incubator. Different concentrations of hyaluronic acid-artesunate polymers were added for 72 hours, and cell apoptosis was detected by flow cytometry.

[0085] Hyaluronic acid-artesunate polymer (HA-ART) has the effect of inhibiting angiogenesis and reducing the release of cytokines such as VEGFR2, PKCα, HIFα, bFGF, and PDGFR in HUVEC cells.

[0086] The release of cytokines such as VEGFR2, PKCα, HIFα, bFGF, and PDGFR was detected by quantitative PCR.

[0087] In the embodiments of the present invention, hyaluronic acid-artesunate polymer (HA-ART) has the effect of inhibiting ocular neovascularization, showing a significant growth inhibition effect on HUVEC cells and a significant inhibitory effect on mouse corneal neovascularization. Hyaluronic acid-artesunate polymer can be used to treat ocular neovascular diseases.

[0088] Specifically, the cell proliferation activity was detected by CCK8 method.

[0089] The corneal neovascularization model was established by suture method in the mouse cornea, and different concentrations of hyaluronic acid-artesunate polymer (HA-ART) were applied to the eyes for 7 days.

[0090] The ocular neovascular diseases include corneal neovascular diseases, iris neovascular diseases, retinal neovascular diseases, choroidal neovascular diseases, neovascular glaucoma and the like.

[0091] It can be seen from the above examples that the expected benefits and commercial value of the technical solution of the present invention after transformation are as follows: the present invention provides theoretical support for the development of related drugs in the later stage and provides a basis for the later drug research and development. Its excellent biocompatibility and tissue penetration will enable the drug to better exert its efficacy. The drug carrier can replace other active drugs and has huge market development potential and huge commercial prospects.

[0092] The technical solution of the present invention fills the technical gap in the industry: currently there are few drugs for inhibiting ocular neovascularization at home and abroad, and most of them are large-molecule antibody compounds, which are expensive and mostly injected, which is inconvenient. The present invention fills the gap of the lack of ocular neovascularization drugs, increases the tissue penetration of the drug, and enhances the drug effect.

[0093] The technical solution of the present invention solves a technical problem that people have been eager to solve but have never been successful: the cornea of ​​the eye and the vitreous body inside the eyeball are barriers that hinder drugs, so that the drugs cannot act well on the relevant parts of the eye. The present invention improves tissue permeability through polyarginine technology, which can make the drug penetrate the eye tissue barrier more, so as to better exert its efficacy. Artesunate has poor tissue compatibility and strong irritation. The present invention improves its tissue compatibility through hyaluronic acid, making it possible for artesunate to act on the eye. It provides a technical basis for the development of artesunate as an ophthalmic drug.

[0094] Example 2: In this embodiment of the present invention, a hyaluronic acid-artesunate-polyarginine nanoparticle is provided.

[0095] Example 3, Synthesis of hyaluronic acid-artesunate polymer (HA-ART). Figure 2 shown.

[0096] Step 1): Dissolve hyaluronic acid (HA, 5 g, 1 eq.) in deionized water and stir at 25°C until the hyaluronic acid is completely dissolved. After the hyaluronic acid is completely dissolved, add the linker adipic acid dihydrazide (ADH, 10.g, 4.5 eq.), adjust the pH of the reaction solution to 4.75 with 0.1 mM hydrochloric acid, then add ethanol in an amount equal to the reaction solution, mix well, add 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC, 1.2 g, 0.5 eq.) and N-hydroxysuccinimide (NHS, 75 mg, 0.5 eq.) in turn, and react at room temperature for 8 hours. After the reaction is completed, 50 mL of 16% sodium chloride salt solution is added and mixed, and four times the volume of the reaction solution of anhydrous ethanol is added to produce a white flocculent precipitate. The precipitate is collected by centrifugation for 10 minutes, and the precipitate is dissolved again by adding an appropriate amount of sodium chloride solution, and the alcohol precipitation is continued. After repeating 3 times, the precipitate is collected and dialyzed for 48 hours, concentrated under reduced pressure, and freeze-dried to obtain a white flocculent substance, which is a hyaluronic acid derivative with an amino group in the carboxyl group of hyaluronic acid (HA-ADH).

[0097] Step 2): Artesunate (ART, 914 mg, 1 eq.) was dissolved in formamide to obtain a light yellow solution, 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC, 456 mg, 1 eq.) and N-hydroxysuccinimide (NHS, 274 mg, 1 e.q.) were added in sequence, and the mixture was reacted at 4°C in the dark for 30 minutes. The hyaluronic acid derivative (HA-ADH, 1.7 g, 0.5 eq.) obtained above was dissolved in an equal volume of dihydrogen sulfoxide and formamide. In methylformamide, add the activated artesunate solution to the hyaluronic acid solution under ice bath, protect from light, and react at 10°C for 12 hours. After the reaction, dialyze in ethanol / water (1:1, v / v) solution using a dialysis bag with a molecular weight cutoff of 3500Da, and change the solution every 8 hours. After one day of dialysis, dialyze with deionized water for another day, and change the water every 8 hours. After dialysis, concentrate and freeze-dry to obtain a light yellow flocculent, which is hyaluronic acid-artesunate polymer (HA-ART).

[0098] Example 4: Structural characterization of hyaluronic acid-artesunate polymer (HA-ART).

[0099] The structural characterization of the hyaluronic acid-artesunate polymer (HA-ART) of the present invention specifically comprises the following steps:

[0100] A. Nuclear magnetic resonance spectroscopy characterization: Take 5 mg of hyaluronic acid-artesunate polymer (HA-ART), add 500 μL of heavy water, freeze-dry, repeat the heavy water exchange 3 times, freeze-dry the product for the last time with heavy water / deuterated DMSO (4:1, v / v) solution and transfer it to a nuclear magnetic resonance tube, and perform nuclear magnetic resonance spectroscopy analysis at 25°C. The results are as follows Figure 3 As shown, characteristic signals of artesunate appear at 5.3-5.7 ppm, and characteristic signals of hyaluronic acid appear at 3.0-4.6 ppm, indicating that the polymer (HA-ART) is formed by covalent coupling of hyaluronic acid and artesunate.

[0101] B. Infrared spectroscopy characterization: Take an appropriate amount of hyaluronic acid-artesunate polymer (HA-ART) and perform infrared spectroscopy characterization using the KBr tablet method. The results are as follows Figure 4 As shown, a weak and narrow absorption peak appears at 1631, indicating that the polymer (HA-ART) is formed by covalent coupling of hyaluronic acid and artesunate.

[0102] Example 5: Synthesis of hyaluronic acid-polyarginine compound (HA-p-Arg). Figure 5 shown.

[0103] Step 1): N'-tert-butyloxycarbonyl-L-ornithine (Boc-Orn, 1 eq.) was dissolved in anhydrous tetrahydrofuran, placed in a pressure bottle, stirred at 25°C, epichlorohydrin (10 eq.) was added, and then triphosgene (0.5 eq.) was slowly added, and the reaction was stirred at room temperature for 3 hours. The reaction was gradually clarified with heat release. After the reaction was completed, 10 mL of cold deionized water was slowly added to quench the triphosgene, and then extracted with ethyl acetate, the organic phase was collected and dried by rotary evaporation, dissolved with 10 mL of anhydrous tetrahydrofuran, 40 mL of anhydrous n-hexane was added to precipitate, the precipitate was collected and dried by rotary evaporation, and the precipitate was collected and dried by rotary evaporation after repeated 3 times. The white powder obtained after rotary evaporation is N'-tert-butyloxycarbonyl-L-ornithine-N-carboxyl ring inner acid anhydride (Boc-Orn-NCA).

[0104] Step 2): Dissolve the hyaluronic acid derivative with an amino group on the carboxyl group of hyaluronic acid (HA-ADH, 1 eq.) in 1 mL of deionized water, add NaCO3 (1 eq.), and stir at 25°C until completely dissolved; use a total volume of 30 mL of a mixed solution of dimethylformamide / chloroform (3:7, v / v) to dissolve N'-tert-butyloxycarbonyl-L-ornithine-N-carboxyl cyclic anhydride (Boc-Orn-NCA, 12 eq.); mix the above two solutions, stir vigorously at room temperature for 12 hours, add 500 mL of cold water after the reaction is completed, collect the precipitate by centrifugation, and dry to obtain a white precipitate, which is a hyaluronic acid-grafted poly-ornithine compound with Boc protection at the end (HA-p-Boc-Orn).

[0105] Step 3): Dissolve the hyaluronic acid grafted poly-ornithine compound with Boc protection at the end (HA-p-Boc-Orn, 900 mg) in 30 mL trifluoroacetic acid, and the reaction solution overflows with bubbles. Stir and react at room temperature for 3 hours. After the reaction, add 300 mL of ether to precipitate a white precipitate, dissolve it in deionized water, and dialyze it using a dialysis bag with a molecular weight cutoff of 3500 Da. Change the water every 8 hours. After dialysis for 48 hours, concentrate and freeze-dry to obtain a powdered hyaluronic acid grafted poly-ornithine compound (HA-p-Orn).

[0106] Step 4): Dissolve the hyaluronic acid grafted polyornithine compound (HA-p-Orn, 1 eq.) in deionized water, slowly add NaOH (10 eq.), stir at room temperature for 3 hours, add methoxyisourea sulfate (30 eq.), react in an oil bath at 65°C for 30 minutes, and after the reaction, purify using a PD-10 gel chromatography column. After the sample solution is freeze-dried, the hyaluronic acid grafted polyarginine compound (HA-p-Arg) is obtained.

[0107] Step 5): Characterize the synthesized hyaluronic acid-polyarginine compound (HA-p-Arg). Figure 6 , Figure 7 shown.

[0108] Example 6: Hyaluronic acid-artesunate-polyarginine nanoparticles.

[0109] The hyaluronic acid-artesunate-polyarginine nanoparticles contain artesunate / polyarginine=0.01-10. The hyaluronic acid-artesunate-polyarginine nanoparticles are firstly obtained by ultrasonically treating a mixture of a hyaluronic acid-artesunate polymer and a hyaluronic acid-polyarginine compound, and then self-assembling. The specific reaction steps are as follows:

[0110] Hyaluronic acid-artesunate polymer (HA-ART) and hyaluronic acid-polyarginine (HA-p-Arg) compound were dissolved in deionized water at a ratio of (1:1, w / w), swollen at 4°C for 12 hours to obtain an emulsion, sonicated on ice (100W, working 3s, rest 5s) for 5 minutes, freeze-dried and dissolved in deionized water, and the emulsion obtained at 4°C was hyaluronic acid-artesunate-polyarginine nanoparticle solution (@HA-ART-p-Arg). The obtained nanoparticles had uniform morphology, as shown in Figure 8 shown.

[0111] Example 7: Hyaluronic acid-artesunate polymer (HA-ART) has the effect of inhibiting angiogenesis, showing an inhibitory effect on the proliferation of human umbilical vein endothelial cells (HUVEC), and the inhibitory effect on cell proliferation is positively correlated with concentration and time, such as Fig. 9 , Fig.10 shown.

[0112] (a): HUVEC cells in the logarithmic growth phase and in good growth condition were taken and 5×10 3 Cells were inoculated into 96-well cell culture plates and cultured overnight in a 37°C, 5% CO2 incubator. Different concentrations of hyaluronic acid-artesunate polymers were added for stimulation for 72 hours. Cell proliferation activity was detected by CCK8 method.

[0113] (b) HUVEC cells in the logarithmic growth phase and in good growth condition were taken and 5×10 5 Cells were inoculated into 6-well cell culture plates and cultured overnight in a 37°C, 5% CO2 incubator. Different concentrations of hyaluronic acid-artesunate polymers were added for 72 hours, and cell apoptosis was detected by flow cytometry.

[0114] Example 6: Hyaluronic acid-artesunate polymer (HA-ART) has the effect of inhibiting angiogenesis, showing that HUVEC cells reduce the release of cytokines such as VEGFR2, PKCα, HIFα, bFGF, PDGFR, etc. Figure 11-Figure 15 shown.

[0115] The release of cytokines such as VEGFR2, PKCα, HIFα, bFGF, and PDGFR was detected by quantitative PCR.

[0116] Example 9: Hyaluronic acid-artesunate polymer (HA-ART) has the effect of inhibiting ocular neovascularization, showing a significant growth inhibitory effect on HUVEC cells and a significant inhibitory effect on mouse corneal neovascularization. Hyaluronic acid-artesunate polymer can be used to treat ocular neovascular diseases, such as Figure 16-Figure 18 shown.

[0117] (a): Cell proliferation activity was detected by CCK8 method.

[0118] (b) A corneal neovascularization model was constructed by suture method on the mouse cornea, and different concentrations of hyaluronic acid-artesunate polymer (HA-ART) were applied to the eyes for 7 days.

[0119] In summary, the hyaluronic acid-artesunate polymer of the present invention is obtained by first reacting the hyaluronic acid carboxyl group with the connecting wall having amino groups and hydrazide groups at both ends to form an amide bond, and introducing amino groups and hydrazide groups, and then newly introducing amino groups and hydrazide groups to form an amide bond with the carboxyl group of artesunate. The method of the present invention has the characteristics of high reaction efficiency, clear product structural characteristics, specific reaction site and no by-products. The hyaluronic acid-artesunate polymer obtained based on this strategy can not only play the role of good drug loading and good tissue compatibility of hyaluronic acid, but also play the role of artesunate activity, and can combine the advantages of the two to achieve the effect of "1+1>2". The hyaluronic acid-artesunate polymer can inhibit the proliferation of human umbilical vein endothelial cells (HUVEC) and promote apoptosis; it can reduce the release of cytokines such as VEGFR2, PKCα, HIFα, bFGF, PDGFR; it has a clear inhibitory effect on the formation of new blood vessels in the cornea of ​​mice. The polymer can be used to prepare ocular anti-neovascular drugs, health products and other sanitary products.

[0120] In the above embodiments, the description of each embodiment has its own emphasis. For parts that are not described or recorded in detail in a certain embodiment, reference can be made to the relevant descriptions of other embodiments.

[0121] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principles of the present invention should be covered within the protection scope of the present invention.

Claims

1. A method for preparing hyaluronic acid-artesunate-polyarginine nanoparticles, characterized in that: The method includes: S1, using adipic acid dihydrazide as a connecting arm, the amino groups at both ends of the adipic acid dihydrazide are connected to the carboxyl group of hyaluronic acid and the carboxyl end of artesunate, respectively, to prepare a hyaluronic acid-artesunate polymer; S2, by ring-opening polymerization of NCA, polyornithine was grafted onto the carboxyl end of hyaluronic acid, and the amino end of ornithine was guanidated to prepare a polymer of hyaluronic acid and polyarginine; S3, preparing hyaluronic acid-artesunate-polyarginine nanoparticles by mixing hyaluronic acid-artesunate and hyaluronic acid-polyarginine compounds using an ultrasonic method; In step S1, the general structural formula of the hyaluronic acid-artesunate polymer is as follows: Wherein, n=1-2500; The hyaluronic acid has a molecular weight of 0.38-100 kDa and is used to prepare artesunate derivatives of different molecular weights and different physical and chemical properties. The disaccharide units of the artesunate derivatives are composed of D-glucuronic acid and N-acetylglucosamine connected by β-1,4 glycosidic bonds, and the disaccharide units are connected by β-1,4 glycosidic bonds. The connecting chain between hyaluronic acid and artesunate derivatives has amino groups and hydrazide groups at both ends of the chain, and a length of 2-12 carbons in the middle, including dihydrazide and diamine compounds, which are used to prepare hyaluronic acid and artesunate covalent conjugates with different bridging arms.

2. The method for preparing hyaluronic acid-artesunate-polyarginine nanoparticles according to claim 1, characterized in that: In step S1, the preparation of hyaluronic acid-artesunate polymer comprises: (1) Dissolve hyaluronic acid HA in deionized water, stir at 25°C until the hyaluronic acid is completely dissolved, add the linker adipic acid dihydrazide ADH after the hyaluronic acid is completely dissolved, adjust the pH value of the reaction liquid to 4-5 with 0.1mM hydrochloric acid, add an equal amount of ethanol to the reaction liquid, mix well, add 1-ethyl-(3-dimethylaminopropyl) carbodiimide EDC and N-hydroxysuccinimide NHS in turn, and react at room temperature for 8 hours; after the reaction is completed, add sodium chloride salt solution, mix well, add anhydrous ethanol to precipitate, centrifuge for 10 minutes, and precipitate; add sodium chloride solution to dissolve again, continue to precipitate, repeat 3 times, collect the precipitate, dialyze for 48 hours, concentrate under reduced pressure, and freeze-dry to obtain hyaluronic acid derivative HA-ADH with amino group in hyaluronic acid carboxyl group; (2) Artesunate was dissolved in formamide, and 1-ethyl-(3-dimethylaminopropyl) carbodiimide EDC and N-hydroxysuccinimide NHS were added in sequence. The mixture was reacted at 4°C in the dark for 30 minutes. The obtained hyaluronic acid derivative HA-ADH was dissolved in dimethylformamide with an equal volume to formamide. The activated artesunate solution was added to the hyaluronic acid solution under ice bath. The mixture was reacted at 10°C in the dark for 12 hours. After the reaction, the mixture was dialyzed in a solution of ethanol: water = 1:1 using a dialysis bag with a molecular weight cutoff of 3500Da. The solution was changed every 8 hours. After one day of dialysis, the mixture was dialyzed with deionized water for one day. The water was changed every 8 hours. After dialysis, the mixture was concentrated and freeze-dried to obtain the hyaluronic acid-artesunate polymer HA-ART.

3. The method for preparing hyaluronic acid-artesunate-polyarginine nanoparticles according to claim 1, characterized in that: In step S2, the general structural formula of the polymer of hyaluronic acid and polyarginine is: Wherein, n=1-2500, m=1-30.

4. The method for preparing hyaluronic acid-artesunate-polyarginine nanoparticles according to claim 3, characterized in that: The preparation method of the polymer of hyaluronic acid and polyarginine comprises: (i) dissolving N'-tert-butyloxycarbonyl-L-ornithine Boc-Orn in anhydrous tetrahydrofuran, stirring at 25° C., adding epichlorohydrin, adding triphosgene, stirring and mixing, and reacting at room temperature for 3 hours; after the reaction, adding cold deionized water to quench the triphosgene, extracting with ethyl acetate, collecting the organic phase and drying it by rotary evaporation, dissolving it in anhydrous tetrahydrofuran, adding anhydrous n-hexane to precipitate, collecting the precipitate and drying it by rotary evaporation, repeating this process for 3 times, collecting the precipitate, and drying it by rotary evaporation to obtain N'-tert-butyloxycarbonyl-L-ornithine-N-carboxyl cyclic anhydride (Boc-Orn-NCA); (ii) dissolving the hyaluronic acid derivative HA-ADH prepared from the hyaluronic acid-artesunate polymer in deionized water, adding NaCO3, and stirring at 25°C until completely dissolved; dissolving Boc-Orn-NCA in a dimethylformamide / chloroform mixed solution; mixing the above two solutions, stirring at room temperature for 12 hours, adding cold water to precipitate after the reaction, collecting the precipitate by centrifugation and drying, and obtaining a hyaluronic acid-grafted polyornithine compound HA-p-Boc-Orn with terminal Boc protection; (iii) dissolving the prepared HA-p-Boc-Orn in trifluoroacetic acid, stirring at room temperature for 3 hours, adding ether to precipitate after the reaction, dissolving with deionized water and dialyzing, concentrating and freeze-drying after dialysis to obtain a hyaluronic acid-grafted polyornithine compound HA-p-Orn; (iv) The prepared HA-p-Orn was dissolved in deionized water, NaOH was added, and the mixture was stirred at room temperature for 3 hours. Methoxyisourea sulfate was added, and the mixture was reacted in an oil bath at 65°C for 30 minutes. After the reaction, the mixture was purified using a gel chromatography column, and the sample solution was freeze-dried to obtain the hyaluronic acid-grafted polyarginine compound HA-p-Arg.

5. The method for preparing hyaluronic acid-artesunate-polyarginine nanoparticles according to claim 2, characterized in that: In step S3, the mixing of hyaluronic acid-artesunate and hyaluronic acid-polyarginine compounds includes: dissolving the hyaluronic acid-artesunate polymer HA-ART and the hyaluronic acid-polyarginine HA-p-Arg compound in deionized water, swelling at 4°C for 12 hours, sonicating on ice, dissolving the freeze-dried powder in deionized water after freeze-drying, and self-packing at 4°C to obtain a hyaluronic acid-artesunate-polyarginine nanoparticle solution @HA-ART-p-Arg.

6. A hyaluronic acid-artesunate-polyarginine nanoparticle, characterized in that: The hyaluronic acid-artesunate-polyarginine nanoparticles are prepared by the preparation method of the hyaluronic acid-artesunate-polyarginine nanoparticles according to any one of claims 1 to 5, wherein the mass ratio of artesunate / polyarginine is 0.01-10; and the hyaluronic acid-artesunate polymer and the hyaluronic acid-polyarginine compound are ultrasonically treated to obtain the hyaluronic acid-artesunate polymer and the hyaluronic acid-polyarginine compound through self-assembly.

7. Use of the hyaluronic acid-artesunate polymer HA-ART in the hyaluronic acid-artesunate-polyarginine nanoparticles according to claim 6 in the preparation of a drug for treating and / or preventing ocular neovascular diseases.

8. The use according to claim 7, characterized in that: The drugs for treating and / or preventing ocular neovascular diseases include drugs for treating and / or preventing corneal neovascular diseases, iris neovascular diseases, retinal neovascular diseases, choroidal neovascular diseases, and neovascular glaucoma diseases.